Lunai Bioworks Inc. — fact timeline

Karen Brink was appointed as Director at Lunai Bioworks Inc..

“On February 11, 2024, the Board appointed Karen Brink, the Chief Growth Officer of GEDi Cube, to the Board, effective upon the closing of the Transaction, to fill the vacancy created by Mr. Grønfeldt-Sørensen’s resignation.”

Henrik Grønfeldt-Sørensen resigned as Director at Lunai Bioworks Inc..

“On February 11, 2024, Henrik Grønfeldt-Sørensen notified the Board of his decision to resign as a director of the Company, effective as of the closing of the Transaction.”

Lunai Bioworks Inc.: Increased authorized shares from 110,000,000 to 360,000,000 and common stock from 100,000,000 to 350,000,000 (effective 2024-02-01).

“On February 1, 2024, Renovaro Biosciences Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Authorized Share Amendment”) to the Company’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of the Company from 110,000,000 to 360,000,000 and to increase the total number of authorized shares of common stock, par value $0.0001 per share, of the Company from 100,000,000 to 350,000,000, effective immediately.”

Lunai Bioworks Inc. shareholders approved Approval to adjourn meeting if necessary for proxy solicitation at the 2024-01-25 meeting.

“Proposal No. 5 : Approval to adjourn the Meeting, if necessary, for the purpose of soliciting additional proxies to approve any one or more of the foregoing proposals to be considered at the Meeting”

Lunai Bioworks Inc. shareholders approved Amendment to 2023 Plan to increase shares available for awards by 5,000,000 at the 2024-01-25 meeting.

“Proposal No. 4 : Approval of an amendment to the 2023 Plan to increase the number of shares of Common Stock available for awards under the 2023 Plan by five million (5,000,000) shares . The stockholders approved this proposal as follows: Votes For 32,145,204 Votes Against 45,717 Abstentions 2,601 Broker Non-Votes 1,394,478”

Lunai Bioworks Inc. shareholders approved Decrease in exercise price of outstanding stock options under the 2019 and 2023 Equity Incentive Plans at the 2024-01-25 meeting.

“Proposal No. 3 : Approval of a decrease in the exercise price of the outstanding stock options held by Renovaro’s employees and consultants granted pursuant to the Enochian BioSciences Inc. 2019 Equity Incentive Plan”

Lunai Bioworks Inc. shareholders approved Amendment to increase authorized shares of capital stock at the 2024-01-25 meeting.

“Proposal No. 2 : Approval of an amendment to Renovaro’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of Renovaro from one hundred ten million (110,000,000) to three hundred sixty million (360,000,000)”

Lunai Bioworks Inc. shareholders approved Approval of issuance of shares of Common Stock pursuant to the Stock Purchase Agreement at the 2024-01-25 meeting.

“Proposal No. 1 : Approval, for purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC (“Nasdasq”), of the issuance of shares of Common Stock , pursuant to the Stock Purchase Agreement”

Avram Miller was appointed as director at Lunai Bioworks Inc..

“appointed Avram Miller to the Board, effective October 11, 2023, to fill a vacancy.”

Ruud Hendriks was appointed as Independent Director at Lunai Bioworks Inc..

“increased the size of the Board to ten members and appointed Leni Boeren and Ruud Hendriks to the Board effective immediately, to fill vacancies created.”

Leni Boeren was appointed as Independent Director at Lunai Bioworks Inc..

“increased the size of the Board to ten members and appointed Leni Boeren and Ruud Hendriks to the Board effective immediately, to fill vacancies created.”

Lunai Bioworks Inc. incurred convertible notes of $2,105,264 with five investors at 12% per annum maturing September 5, 2024.

“Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12%”

Lunai Bioworks Inc. entered into Subscription Agreements with five investors valued at aggregate principal amount of $2,105,264 (effective 2023-09-05).

“Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264.”

Lunai Bioworks Inc. entered into Purchase Agreement with GEDi Cube Intl Ltd. (effective 2023-09-28).

“On September 28, 2023, Renovaro Biosciences Inc. (NASDAQ: RENB) (“ Renovaro ”), entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with GEDi Cube Intl Ltd.”

Lunai Bioworks Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock establishing rights and preferences (effective 2023-08-01).

“On August 1, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Certificate of Designation ”) establishing the series of Preferred Stock designated as the Series A Convertible Preferred Stock with the rights and preferences discussed below.”

Lunai Bioworks Inc.: Changed corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc (effective 2023-08-01).

“On August 1, 2023, at 5:04 P.M. Eastern Time, Enochian Biosciences Inc. filed with the Secretary of the State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation to change its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc., effective immediately.”

Lunai Bioworks Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-07-21 meeting.

“Proposal No. 3 : Ratification of Independent Registered Public Accounting Firm . The stockholders ratified Sadler, Gibb & Associates, LLC as the Company's independent registered public accounting firm as follows: Votes For 20,327,508 Votes Against 16,107 Abstentions 13,456”

Lunai Bioworks Inc. shareholders approved Approval of 2023 Equity Incentive Plan at the 2023-07-21 meeting.

“Proposal No. 2 : Approval of 2023 Equity Incentive Plan . The stockholders approved the 2023 Equity Incentive Plan as follows: Votes For 18,785,519 Votes Against 34,914 Abstentions 8,269 Broker Non-Votes 1,528,369”

Lunai Bioworks Inc. shareholders approved Election of Directors at the 2023-07-21 meeting.

“Proposal No. 1 : The election of Renè Sindlev, Dr. Mark R. Dybul, Dr. Carol L. Brosgart, Gregg Alton, James Sapirstein, Henrik Gronfeldt-Sorensen and Jayne McNicol for terms until the next annual meeting of stockholders or until each such director's successor shall have been duly elected and qualified . The stockholders elected each of the seven directors by the following votes: Director Votes For Votes Withheld Broker Non-Votes Renè Sindlev 18,661,936 166,766 1,528,369 Dr. Mark R. Dybul 18,662,825 165,877 1,528,369 Dr. Carol L. Brosgart 18,652,095 176,607 1,528,369 Gregg Alton 17,343,287 1,485,415 1,528,369 James Sapirstein 17,122,111 1,706,591 1,528,369 Henrik Gronfeldt-Sorensen 18,659,827 168,875 1,528,369 Jayne McNicol 17,247,573 1,581,129 1,528,369”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 7, 2023, Enochian Biosciences Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital”

Lunai Bioworks Inc.: Amended and restated Article I, Section 7 of Bylaws to lower the quorum requirement for stockholder meetings from a majority of outstanding shares to one-third (effective 2023-07-07).

“The Amended and Restated Bylaws amends and restates Article I, Section 7 of the Company’s existing Bylaws in its entirety to lower the number of holders of the shares entitled to vote at a meeting of stockholders constituting a quorum, in person or by proxy, from a majority of the holders of the Company’s outstanding stock to one-third of the holders of the Company’s outstanding stock.”

Lunai Bioworks Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to Twenty Million Dollars ($20,000,000) (effective 2023-06-20).

“Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park”

Lunai Bioworks Inc. entered into Security Agreement with Paseco ApS (effective 2022-12-30).

“On February 16, 2023, the Company entered into a security agreement between the Company and the Holder, effective as of December 30, 2022 (the “ Security Agreement ”) under which the Company pledged and granted the Holder a first priority security interest in and lien upon all of the Company’s wholly-owned assets as collateral security for the prompt payment in full of the principal amounts of the February Notes and the March Note when due.”

Lunai Bioworks Inc. amended Amendment to the March Note with Paseco ApS valued at $5,000,000 (effective 2022-12-30).

“On February 16, 2023, the Company amended that certain promissory note dated March 30, 2020 in the principal amount of $5,000,000 between the Company and the Holder (the “ March Note ”).”

Lunai Bioworks Inc. amended Amended and Restated February Notes with Paseco ApS valued at $600,000 (effective 2022-12-30).

“On February 16, 2023, the Company amended and restated those two certain convertible promissory notes between the Company and Paseco ApS (the “ Holder ”) dated February 6, 2020, each in the principal amount of $600,000 (the “ February Notes ”) by entering into two amended and restated secured convertible promissory notes, each with an effective date of December 30, 2022 and each in the principal amount of $600,000 (the “ Amended and Restated February Notes ”).”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 16, 2023, the Company received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co”

Francois Binette was appointed as Chief Operating Officer at Lunai Bioworks Inc..

“On October 18, 2022, the Company appointed Francois Binette PhD, age 59, as Chief Operating Officer of the Company, effective November 1, 2022.”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 23, 2022, Enochian Biosciences Inc. (the “ Company ”) received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”)stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 1”

Carl Sandler resigned as member of the Board of Directors at Lunai Bioworks Inc..

“On March 25, 2022, Carl Sandler provided notice of his resignation as a member of the Board of Directors of Enochian Biosciences Inc.”